China’s NMPA approves Sanofi’s rare haematologic disease treatments
The NMPA’s decision is supported by data from the ATLAS Phase III trials.
Drug Development
Zealand Pharma and OTR to develop metabolic disease therapeutics
Pfizer plans job cuts in Switzerland to reduce expenses
Boehringer’s Jascayd gains China’s NMPA approval for PPF
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor
Formycon and Zydus sign exclusive agreement for FYB206 supply
Health Canada approves Biogen’s Zurzuvae for PPD treatment
EC approves Roche’s Gazyva to treat active lupus nephritis
